Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares his excitement towards the EBMT-EHA CAR T-cell Meeting taking place on February 10-12 2022. This meeting is an opportunity to hear about the latest updates in chimeric antigen receptor T-cell (CAR-T) therapies, including discussions about the place of CAR-T therapy in the treatment regimen and treatment sequencing, and talks on novel CAR platforms, allogeneic CAR-Ts and new target antigens. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.